Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CXCL8 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CXCL8/IL-8 Recombinant Protein HEK293 expressed, monomeric active conformation, sequence verified, high purity (>95%), endotoxin controlled (<1.0 EU/μg). For SPR/BLI binding assays. |
View CXCL8 Products |
| Gene Delivery | CXCR1 & CXCR2 Lentivirus Premade Particles Full-length ORF for stable cell line construction. Crucial for GPCR calcium flux and chemotaxis assays. |
View CXCR1 Products |
| Benchmark Ab | Anti-CXCL8 Recombinant Antibody Biosimilar sequence based on BMS-986253 (HuMax-IL8). Recombinant positive control for neutralization assays. |
View CXCL8 Products |
| Validator | CXCL8 siRNA Set Target-specific knockdown pool for validation of target specificity in primary cells. |
View CXCL8 Products |
| Related Target A | CXCR1 High-affinity GPCR receptor for CXCL8. Primary mediator of neutrophil chemotaxis. |
View CXCR1 Products |
| Related Target B | CXCR2 Low-affinity, high-capacity GPCR receptor for CXCL8. Key driver of tumor angiogenesis and MDSC recruitment. |
View CXCR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species ortholog evaluation (Human vs. Cyno) | Human and Cynomolgus CXCL8 ortholog proteins strictly sequence verified with high purity (>95%) for cross-reactivity profiling. |
| Subfamily counter screening (CXCL1-7 selectivity) | Comprehensive CXC chemokine family protein panel available, verified by mass spectrometry to ensure zero cross-contamination. |
| Lack of functional validation controls | Clinical Benchmark Antibody (BMS-986253 biosimilar) included as a functional assay positive control. |
| False positives in cell-based assays | Sequence-specific siRNA pool included for target-specific knockdown verification in complex co-cultures. |
Live CXCL8/IL-8/IL8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CXCL8/IL-8 therapeutics is intensifying, with major players shifting focus from traditional inflammatory indications to oncology combinations, particularly targeting the immunosuppressive tumor microenvironment (TME). As first-generation monoclonal antibodies reach advanced clinical phases, the next wave of R&D is targeting the dual inhibition of CXCL8 receptors (CXCR1/CXCR2) or designing bispecific antibodies combining CXCL8 neutralization with immune checkpoint blockade.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Bristol Myers Squibb (BMS-986253) | Advanced Solid Tumors, Melanoma | High-affinity neutralization assays (Need high-purity, native-glycosylated CXCL8 recombinant protein) |
| Small Molecule (GPCR Antagonist) | Dompé Farmaceutici (Reparixin), Syntrix (SX-682) | Breast Cancer, Metastatic Melanoma | Functional GPCR screening (Need CXCR1/CXCR2 Lentivirus for stable cell line generation) |
| Bispecific / Combination | Academic & Biopharma Consortia | ICI-Resistant Solid Tumors | Simultaneous binding assays (Need sequence-verified antigens and benchmark controls) |